Skip to search formSkip to main contentSkip to account menu

tipifarnib

Known as: (+)-6-[Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, (R)-6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, 2 (1H))-quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-,(+)- 
A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an… 
National Institutes of Health

Related topics

Related topics

11 relations
Angiogenesis InhibitionInhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPositive Regulation of Apoptosis

Broader (2)

Antineoplastic AgentsQuinolones

Narrower (2)

R115777Zarnestra

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas
Pirfenidone, an oral anti‐inflammatory, antifibrotic agent with activity in idiopathic pulmonary fibrosis, may mediate anti‐tumor… 
2010
2010
Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy.
Review
2010
Review
2010
Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib
Importance of the field: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) incidence in the United States increases… 
2008
2008
Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features
Purpose: Acute myelogenous leukemia (AML) does not have a high cure rate, particularly in patients with poor-risk features. Such… 
Highly Cited
2008
Highly Cited
2008
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
BACKGROUND Keratoacanthomas, as well as an actinic keratosis progressing to squamous cell cancer, have been reported in patients… 
Review
2007
Review
2007
Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives.
2004
2004
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
PURPOSE Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, has activity in hematologic malignancies, but the… 
Highly Cited
2004
Highly Cited
2004
Tipifarnib (ZARNESTRATM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.
Farnesyltransferase inhibitors (FTI) make up a novel class of anti-cancer agents that competitively and selectively inhibit… 
2004
2004
Design, synthesis, and activity of 4-quinolone and pyridone compounds as nonthiol-containing farnesyltransferase inhibitors.
Highly Cited
2002
Highly Cited
2002
Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3…
Accelerator mass spectrometry (AMS) has been used in a human mass balance and metabolism study to analyze samples taken from four… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)